Novel Psychoactives, Umbilical Cord Tissue
Use
Part of the Comprehensive Drug Screen, Umbilical Cord Tissue profile; used to detect novel psychoactive substances in neonatal umbilical cord tissue to assess in utero exposure. This aids in identifying maternal substance use during the later stages of pregnancy, with clinical relevance for neonatal toxicology evaluation.
Special Instructions
Only orderable as part of the profile Comprehensive Drug Screen, Umbilical Cord Tissue (FCDSU); confirmation testing may be performed at no additional charge; test setup info available for laboratory information system interfacing.
Limitations
This test is not orderable separately; specimen requirements and performance are determined by the parent profile; reporting limits are determined per analysis; compliance determined by performance characteristics established by NMS Labs, not FDA cleared.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 97216-6
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
All specimens will be evaluated by the processing and performing laboratories for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 14 days |